Becton, Dickinson and CompanyNYSE: BDX

On June 12, 2026, Bank of America lowered its Becton Dickinson price target to $170 from $177, keeping the stock under pressure even after a solid fiscal Q2 print. BDX had posted Q2 FY2026 adjusted EPS of $2.90 versus the $2.78 estimate, with revenue of $4.7B up 2.6% FX-neutral, and raised full-year EPS guidance to $12.52-$12.72. However, adjusted gross margin fell 90 bps to 54.7% and operating margin dropped 110 bps to 24.2% year-over-year on tariff pressures and market headwinds. The stock traded around $146 as of June 13, near the low end of its 52-week range. The risk is that tariff-driven margin erosion offsets the top-line growth and the planned biosciences/diagnostics separation, keeping sentiment cautious despite an average PT of ~$180.

Becton, Dickinson and Company (BDX) Stock Price, News & Analysismarketbeat.comBecton, Dickinson and Company (BDX) Stock Price, Quote, News & Analysisseekingalpha.com

No material news in the last 48 hours.

No material news in the last 48 hours.

No material news in the last 48 hours.

No material news in the last 48 hours.

Becton Dickinson named Vitor Roque EVP and CFO effective May 7, 2026, after serving as interim CFO since December 2025. The company posted Q2 FY2026 revenue of $4.714B (up 5.2%) and adjusted EPS of $2.90, beating $2.78 consensus. BDX executed a $2.0B accelerated share repurchase, retired $2.1B of debt, and raised full-year adjusted EPS guidance to $12.52-$12.72. On May 5, BD announced a strategic partnership with Wellstar Health System. New EVP Peter Menziuso named president of BD Interventional on May 18. Barclays raised its price target to $204.

BD Q2 FY26 EPS Beatinvesting.comBD Appoints Vitor Roque CFOprnewswire.comBDX Q2 Results and FY2026 Outlookquiverquant.com

No material news in the last 48 hours.

On May 18, 2026, Becton Dickinson named Peter Menziuso EVP and president of BD Interventional, succeeding Rick Byrd who is retiring after nearly 25 years. The appointment follows BD's May 7 Q2 FY26 results in which the company beat with $2.90 adjusted EPS, raised full-year adjusted EPS guidance to $12.52-$12.72, executed a $2.0B ASR, and retired $2.1B of debt. Barclays raised its price target to $204 on the strong Q2 print. Bear case: the Interventional segment is undergoing leadership turnover at a time when device-segment growth must accelerate to meet raised guidance.

BD Reports Second Quarter Fiscal 2026 Financial Resultsinvestors.bd.comBecton Dickinson & (BDX) Stock News & Updatesstocktitan.net

No material news in the last 48 hours. BDX traded with a Buy consensus rating as of May 18 at around $143. Q2 FY2026 results on May 7 beat expectations with adjusted EPS of $2.90, and full-year guidance was raised to $12.52-$12.72.

Becton Dickinson Q2 2026 Earnings Transcript - Globe and Mailtheglobeandmail.comBDX jumps after Q2 results and raised FY2026 EPS outlook - QuiverQuantquiverquant.comBDX Stock Forecast - Public.compublic.com

Becton, Dickinson reported fiscal Q2 revenue of $4.71B and adjusted EPS of $2.90, beating estimates, and raised FY adjusted EPS guidance to $12.52-$12.72 despite divestiture headwinds and a net loss. Vitor Roque, who has served as interim CFO since December 2025, was named permanent EVP and CFO effective May 7. The company received multi-category supply chain resilience awards, launched the HemoSphere Stream Module for continuous noninvasive blood pressure monitoring, highlighted new PureWick clinical data, and advanced its Liverty TIPS Stent Graft program in portal hypertension. Barclays raised PT to $204 from $202 with Overweight. Analyst consensus is Buy with $184.69 average 12-month PT (~28% upside). Risk: ongoing Alaris and divestiture pressures.

Becton Dickinson price target raised to $204 from $202 at Barclaystipranks.comHow Investors May Respond To Becton Dickinson (BDX) Expanding Clinically Differentiated Devicessimplywall.stBDX Maintained by Barclays -- Price Target Raised to $204gurufocus.com

BD reported Q2 fiscal 2026 results on May 7 with revenue of $4.714B, up 5.2% reported (2.6% currency-neutral), and adjusted diluted EPS of $2.90 (GAAP diluted EPS of -$0.13). The company raised full-year adjusted EPS guidance to $12.52-$12.72, reaffirmed revenue guidance, executed a $2.0B accelerated share repurchase, and retired $2.1B of debt. BD named Vitor Roque (interim CFO since December 2025) as permanent EVP and CFO effective May 7, while Rick Byrd will retire after nearly 25 years (remaining through June 2026). On May 5, BD announced a strategic partnership with Wellstar Health System to integrate BD Pyxis Pro dispensing and BD Alaris infusion technologies with AI-powered medication inventory visibility. Barclays raised its PT to $204 from $202 with an Overweight rating post-earnings. Stock traded at $143.15 on May 11.

BD Reports Second Quarter Fiscal 2026 Financial Resultsinvestors.bd.comBDX jumps after Q2 results and raised FY2026 EPS outlookquiverquant.comBecton Dickinson price target raised to $204 from $202 at Barclaystipranks.com

BD reported Q2 FY2026 revenue of $4.714 billion (up 5.2% reported, 2.6% currency-neutral) with adjusted diluted EPS of $2.90 versus consensus of $2.78. The company raised its full-year adjusted EPS guidance to $12.52-$12.72 and reaffirmed revenue growth expectations. Effective May 7, 2026, BD named Vitor Roque executive vice president and CFO, after he served as interim CFO since December 2025. On May 5, BD announced a strategic partnership with Wellstar Health System to integrate BD Pyxis Pro dispensing and BD Alaris infusion technologies, powered by AI in BD Incada. BD also completed the divestiture of its Biosciences & Diagnostic Solutions business. Year-to-date the company has returned $2.3 billion to shareholders. The stock closed at $143.15 on May 11.

BD Reports Second Quarter Fiscal 2026 Financial Resultsinvestors.bd.comBD Appoints Vitor Roque Chief Financial Officerprnewswire.comBDX jumps after Q2 results and raised FY2026 EPS outlookquiverquant.com

BD reported Q2 FY2026 results on May 7: revenue of $4.71B (+5.2% reported / +2.6% FX-neutral) and adjusted EPS of $2.90 beating $2.78 consensus (4.5% beat). More than 90% of the portfolio delivered mid-single-digit growth; double-digit growth in biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration. Adjusted operating margin 24.2%. BD raised FY26 adjusted EPS guidance to $12.52-$12.72 (from $12.35-$12.65). Vitor Roque named permanent EVP and CFO effective May 7 after internal/external search. Management confirmed Life Sciences separation has concluded. BD presented at Bank of America Healthcare Conference on May 12. Stock up 5.7% on results.

BD Reports Second Quarter Fiscal 2026 Financial Resultsinvestors.bd.comBDX jumps after Q2 results and raised FY2026 EPS outlookquiverquant.comBecton Dickinson (BDX) Q2 2026 Earnings Transcriptfool.com